# John C. McCormick

> John C. McCormick is a Series B investor at InnovaHealth Partners backing Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [InnovaHealth Partners](https://shizune.co/investors/profile/innovahealth-partners)
- Location: New York, United States
- Total investments: 5
- Last investment: Jan 2017
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/john-mccormick-ba57a3114

John C. McCormick is a Series B investor at InnovaHealth Partners in New York focused on Medical and Biotechnology. Mr. McCormick's is the Managing Director at InnovaHealth Partners, LP. He attended MIT Sloan School of Management.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 20% |
| Biotechnology | 1 | 20% |
| Manufacturing | 1 | 20% |
| Developer Platform | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Private Equity | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $15M | Series C | Jan 12, 2017 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12M | Series C | May 04, 2016 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $5M | Series B | Jan 23, 2014 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $12.5M | Series B | May 29, 2013 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. |  | Private Equity | Apr 30, 2012 |  |

5 of 5 investments shown.

## Co-investors
- [S3 Ventures](https://shizune.co/investors/profile/s3-ventures) — VC Fund, 5 deals together
- [Houston Angel Network](https://shizune.co/investors/profile/houston-angel-network) — VC Fund, 1 deal together
- [Piper Sandler](https://shizune.co/investors/profile/piper-jaffray) — VC Fund, 1 deal together

## About InnovaHealth Partners

VC Fund · New York, United States

InnovaHealth Partners is an investment firm concentrating on growth buyouts of late stage medical technology companies.

2 contacts available at InnovaHealth Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Ariella Golomb | Partner & Founder | https://shizune.co/investors/profile/ariella-golomb |
| John C. McCormick | Managing Director | https://shizune.co/investors/profile/john-c-mccormick |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does John C. McCormick invest in?

John C. McCormick invests primarily in Medical, Biotechnology and Manufacturing startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did John C. McCormick last invest?

The most recent investment recorded for John C. McCormick closed in Jan 2017. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co